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Abstract 
 
Cardiovascular disease (CVD) is rated as a leading cause of death, particularly 
in industrialised countries. Atherosclerosis is a common cause of CVD. There-
fore, several mechanisms leading to atherosclerosis development are covered 
in this thesis. The aim of the thesis project was to investigate the regulation of 
the low-density lipoprotein receptor (LDL-R) gene family expression in human 
coronary artery endothelial cells (HCAEC) and human coronary artery smooth 
muscle cells (HCASMC). The study focused on the LDL-R, VLDL-R, LRP1, and 
LRP2 and included the influence of several factors which have been suggested 
to play a role in atherosclerosis: modified lipoproteins (in this study carbamylat-
ed LDL), estrogen, and alterations of vascular shear stress.  
Carbamylated LDL is considered as a risk factor since patients with chronic kid-
ney disease are prone to develop CVD (“uremia-induced atherosclerosis”). Low 
shear stress is believed to act atherogenic because of its numerous unfavoura-
ble effects on endothelial function. Actually, atherosclerotic lesions occur pref-
erentially at regions with low vascular shear stress. In contrast, estrogen is sug-
gested to be responsible for the lower incidence of atherosclerosis in premeno-
pausal women. Thus, atheroprotective properties are attributed to the steroid 
hormone. 
Human coronary artery endothelial cells were cultivated under static and dy-
namic (high and low shear stress) conditions, human coronary artery smooth 
muscle cells were cultivated under static conditions. Then, the cells were treat-
ed with native and carbamylated lipoproteins and 17β-estradiol in different com-
binations. The receptor gene expression levels in these cells were analysed by 
real-time quantitative PCR. Furthermore, protein detection by Western-blot, lip-
oprotein modification analysis by relative electrophoretic mobility determination 
and cytotoxicity assays should complete the studies.  
In summary, significant alterations in gene expression of both cell types could 
be determined. These findings provide further evidence for a crucial role of car-
bamylated LDL, estrogen, and shear stress in disease development.  
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Zusammenfassung 
 
Kardiovaskuläre Erkrankungen zählen zu den führenden Todesursachen in den 
Industriestaaten. Sie werden häufig durch die multifaktorielle Erkrankung 
Atherosklerose verursacht, weswegen in dieser Arbeit einige Faktoren unter-
sucht werden sollen, die zur Entwicklung dieser Krankheit beitragen. Das Ziel 
dieses Projekts ist die Untersuchung der Expression der LDL-Rezeptor-
Genfamilie und ihrer Regulation in Endothelzellen und glatten Muskelzellen der 
menschlichen Koronararterien. Die Studie konzentrierte sich dabei auf den LDL-
R, VLDL-R, LRP1 und LRP2 und behandelte den Einfluss von mehreren Fakto-
ren, die für die Entstehung von Atherosklerose von Bedeutung sein sollen: mo-
difizierte Lipoproteine (in dieser Studie carbamyliertes LDL), Östrogen und Ver-
änderungen der auf die Gefäßwand wirkenden Scherkräfte („shear stress“).  
Carbamyliertes LDL gilt als Risikofaktor, da Patienten mit chronischen Nie-
renerkrankungen eine kardiovaskuläre Erkrankung entwickeln („Urämie-
induzierte Atherosklerose“). Verminderter „shear stress“ wird aufgrund seiner 
zahlreichen negativen Auswirkungen auf die Endothelfunktion ebenfalls als 
atherogen eingestuft. Tatsächlich treten Läsionen bevorzugt in Gefäßbereichen 
auf, in denen geringere Scherkräfte wirken. Östrogen werden zahlreiche 
atheroprotektive Funktionen zugeschrieben. Das Steroidhormon wird daher für 
die geringere Inzidenz von Atherosklerose in prämenopausalen Frauen verant-
wortlich gemacht. 
Endothelzellen wurden unter statischen und dynamischen Bedingungen kulti-
viert, glatte Muskelzellen unter statischen Bedingungen. Anschließend wurden 
beide Zelltypen mit verschiedenen Kombinationen von nativen und carbamylier-
ten Lipoproteinen und 17β-Estradiol behandelt. Die Genexpression der Rezep-
toren wurde mittels quantitativer RT-PCR ermittelt. Ein Proteinnachweis mittels 
Western-blot sowie eine Lipoprotein-Modifikationanalyse mittels Elektrophorese 
(„relative mobility“) und Zytotoxizitätstests sollten die Untersuchung ergänzen.  
Zusammengefasst konnten signifikante Änderungen der Genexpression festge-
stellt werden. Diese Erkenntnisse sind als weiterer Hinweis auf eine wichtige 
Rolle der untersuchten Faktoren in der Krankheitsentstehung zu bewerten.  
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1. Introduction 
 
1.1 Atherosclerosis  
Atherosclerosis has become a major health problem, especially in industrialised 
countries. This inflammatory disease is characterised by the progressive accu-
mulation of lipids and the development of atheromatous plaques in the vessel 
wall. Resulting in cardiovascular disease like myocardial infarction and stroke, it 
is rated as a leading cause of death. This chapter will refer to disease develop-
ment, mechanisms, and risk factors.  
Fig. 1: Formation of atherosclerotic lesions, took from [1]. 
a) the normal artery wall 
b) adhesion and entry of monocytes, foam cell formation by lipid uptake 
c) migration and proliferation of smooth muscle cells, formation of a fibrous cap 
d) plaque rupture and thrombus formation 
 
1.1.1 The healthy artery wall and endothelial function 
The normal arterial wall is built up of three layers (see fig. 1a). A monolayer of 
endothelial cells (EC) lines the tunica intima that contains resident smooth mus-
cle cells (SMC). The middle layer, termed tunica media, comprises smooth 
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muscle cells in an extracellular matrix (ECM). Fibroblasts, mast cells, mi-
crovessels, and nerve endings are located in the outermost layer (adventitia) [1]. 
In the healthy artery, endothelial cells perform atheroprotective functions medi-
ated by endothelial nitric oxide synthase (eNOS). They resist adhesion and ag-
gregation of inflammatory cells and platelets, control the vascular tone and 
promote fibrinolysis [2]. More precisely, nitric oxide (NO) induces vasodilation, 
inhibits platelet activation, and blocks the expression of adhesion molecules 
(vascular cell adhesion molecule VCAM-1, intracellular adhesion molecule 
ICAM-1) as well as inflammatory molecules regulated by nuclear factor kappa B 
(NF-κB). However, constant exposure to risk factors (hypertension, hyper-
lipidemia, obesity, smoking, insulin resistance, inflammation) results in eNOS 
decrease, a feature of endothelial dysfunction [3]. 
1.1.2 The onset of atherosclerosis 
The initial steps of the disease are characterised by the capture of monocytes 
on the EC surfaces and the entry of lipoprotein particles in the artery wall (see 
fig. 1b). The expression of adhesion molecules is provoked by irritating stimuli 
like dyslipoproteinemia, hypertension, and pro-inflammatory mediators. Simul-
taneous changes in ECM composition and endothelial permeability advance en-
try and retention of LDL particles in the artery wall [4]. LDL is supposed to show 
an increased affinity for ECM components, especially chondroitin sulphate pro-
teoglycans, leading to interaction, retention and aggregation [5]. The resulting 
complexes of lipoproteins and proteoglycans are prone to modifications (aggre-
gation, oxidation, enzymatic cleavage) and therefore considered as pro-
atherogenic [3].  
Monocytes are attracted by the chemokine MCP-1 (macrophage chemoattract-
ant protein 1) [6]. After binding to the endothelial surface and migration into the 
tunica intima, they differentiate to macrophages by colony stimulating factor 
(CSF). Subsequently, they start to engulf LDL particles and become “foam cells” 
(intracellular lipid droplets formed by cholesterol esters cause a foamy appear-
ance) [1]. The uptake of modified lipoprotein particles is mediated by scavenger 
receptors [7] and also by LRP1 [8]. Foam cells release growth factors, cytokines, 
matrix-metalloproteases, reactive oxygen species (ROS) and tissue factors (TF) 
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maintaining the inflammatory response. Moreover, these factors induce vascu-
lar remodelling and elevate the susceptibility to thrombus formation [3].  
1.1.3 Disease progression and thrombosis 
Lesion progression implies the recruitment of SMC from tunica media to the tu-
nica intima (see fig. 1c), where SMC proliferation is induced by mediators such 
as platelet-derived growth factor (PDGF). Furthermore, the SMC form ECM 
molecules (interstitial collagen and elastin). As a consequence, the plaque is 
covered by a fibrous cap [1]. Dying foam cells located under this cap release 
lipids that accumulate extracellularly and contribute to necrotic core formation 
[9]. When influenced by atherogenic stimuli, SMC undergo a transformation 
from the non-proliferative, contractile phenotype into actively proliferating cells 
leading to vascular remodelling and intimal thickening [3].  
Plaques cause medical problems by developing blood-flow limiting stenoses 
leading to tissue ischemia. In addition, they can interrupt the blood flow by elicit-
ing thrombi. A thrombus arises when the fibrous cap ruptures (see fig. 1d) lead-
ing to an exposition of the core’s pro-coagulant substances to coagulation pro-
teins in the blood [10].  
 
1.2 Lipoproteins 
Lipoproteins are of particular importance for atherosclerosis since a strong as-
sociation between CVD and plasma lipid levels has been observed [11]. 
1.2.1Structure and classification of lipoproteins 
Lipoproteins facilitate the transport of hydrophobic lipids in the blood. As illus-
trated in fig. 2 and fig. 3, these spherical molecule complexes consist of a hy-
drophilic shell (phospholipids, cholesterol, apolipoproteins) and a hydrophobic 
core (triglycerides, cholesterol esters). They differ in density, size, place of as-
sembly, lipid composition, and apolipoprotein classes. Usually, they are classi-
fied by their density (see fig. 4). Each lipoprotein class has its specific apolipo-
proteins, which serve as structural elements and stabilize lipid emulsions. Fur-
thermore, they mediate synthesis and degradation of lipoproteins by enzyme 
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activation and serve as ligands for lipoprotein receptors in membranes of target 
cells [12, 13]. 
Fig. 2: Structure of a lipoprotein [14].     Fig.3: LDL and its apoprotein B100 [15]. 
 
 
 
 
                  Fig. 4: Overview of lipoproteins and their characteristics [16]. 
 
 
1.2.2 The lipoprotein metabolism (illustrated in fig. 5) 
Ingested lipids are transported by chylomicrons from the intestine into the pe-
riphery. Then, lipoproteinlipase (LPL) is activated by apolipoprotein (Apo) CII 
leading to a release of free fatty acids, which are absorbed by body cells. The 
cholesterol-rich chylomicron-remnants are taken up by the liver by binding to 
ApoE receptors. The liver exports triglycerides and cholesterol in very-low den-
sity lipoprotein (VLDL) particles, which deliver fatty acids to the periphery also 
using the mechanism of LPL activation. Approximately 50% of the VLDL-
remnants (also called intermediate density lipoprotein (IDL)) are converted to 
low-density lipoprotein (LDL) by hepatic lipase. LDL is responsible for choles-
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terol transport to peripheral tissues, where it regulates the de-novo cholesterol 
synthesis. LDL uptake by receptor-mediated endocytosis is shown in figure 6 
and figure 7. It requires the binding of ApoB-100 to the LDL receptor. The re-
ceptor-LDL-complex is internalised in a vesicle that fuses with a lysosome. The 
LDL is hydrolysed whereby free cholesterol enters the cytoplasm and the LDL 
receptor goes back to the membrane. The resulting free cholesterol acts as 
regulator for cellular cholesterol homeostasis. The particular mechanisms are 
described in figure 6. High-density lipoprotein (HDL) is responsible for reverse 
cholesterol transport. ApoAI on HDL activates lecithin-cholesterol-
acyltransferase (LCAT), which esterifies cholesterol. Thus, excess cholesterol is 
eliminated from the blood and transported to the liver. In addition, HDL exerts 
several other beneficial functions (see fig. 8) [12, 13]. 
 
Fig. 5: Lipoprotein metabolism, took from [17]. 
Fatty acids are transported from the intestine to the blood via chylomicrons. These particles 
supply peripheral tissues with fatty acids. Chylomicron remnants are absorbed by the liver. The 
liver releases VLDL particles for delivering fatty acids to adipose tissue and muscles. Their 
remnants are partly converted to LDL, which is internalized by the LDL receptors of the liver or 
extrahepatic tissues. HDL mediates the transport of cholesterol back to the liver.  
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Fig. 6: Regulatory actions of dietary cholesterol [18]. 
The LDL receptor binds LDL via apoB100. This complex is internalized (“clathrin-coated pits”) in 
a vesicle and hydrolysed in a lysosome. The released cholesterol executes regulatory functions: 
to maintain cellular cholesterol homeostasis, it accelerates cholesterol esterification by activat-
ing ACAT (Acyl-CoA-Cholesterin-Acyltransferase) and blocks HMG CoA reductase (3-hydroxyl-
3-methyl-glutaryl-CoA reductase), the enzyme responsible for endogenous cholesterol synthe-
sis. In addition, it reduces the number of LDL receptors to decrease further cholesterol uptake. 
The sterol regulatory element binding protein (SREBP) transcription factors have a crucial role 
in these regulatory actions. 
 
 
Fig. 7: The cycle of the LDL receptor [19]. 
After cholesterol release, the receptor is recycled and goes back to the membrane. 
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Fig. 8: Protective effects of HDL concerning atherosclerosis and thrombosis [3]. 
 
 
1.3 The LDL receptor gene family 
 
The members of the LDL receptor gene family are transmembrane receptors 
that share structural and functional properties. They are expressed on the cell 
surface and interact with several ligands via specific extracellular binding sites. 
After receptor internalization by coated pits, these ligands are transported to ly-
sosomes and degraded. Fig. 9 visualizes the structure of the receptor family: 
they consist of ligand binding repeats, epidermal growth factor (EGF) precursor 
repeats, YWTD repeats (“β-propeller”), a single transmembrane domain, and a 
short cytoplasmic tail containing internalization signals [20, 21]. 
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Fig. 9: The structure of the LDL receptor gene family [22] 
 
1.3.1 The low-density lipoprotein receptor (LDL-R) 
The LDL receptor was discovered in the 1970s by Brown and Goldstein, who 
did research on familial hypercholesteremia (FH) and the regulation of the lipo-
protein metabolism in fibroblasts [23-29]. This integral membrane glycoprotein 
is made up of 839 amino acids and binds lipoproteins containing apoB-100 and 
apoE. Additionally, it contains an O-linked sugar domain, which is not shared by 
all family members. Its main responsibility is to mediate lipoprotein uptake of the 
cells (see fig. 6 and fig. 7). LDL receptor defects lead to disturbances of the lip-
oprotein metabolism. For example, patients with FH suffer from high cholesterol 
levels due to a lack of functional receptors [18, 30]. Therefore, it is self-evident 
that a sufficient lipoprotein clearance by the LDL receptor is crucial for mainte-
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nance of the health of the arterial wall. The influence of various factors on the 
LDL receptor’s expression level has to be investigated for that reason. 
  
1.3.2 The very-low-density lipoprotein receptor (VLDL-R) 
The VLDL receptor was discovered in the group of T. Yamamoto in 1992 [31]. 
This receptor consists of 846 amino acids and differs from the LDL receptor just 
by possessing one additional ligand-binding domain. It was found to be highly 
expressed in the heart, skeletal muscle, and adipose tissue but not in the liver. 
Therefore, it was suggested to supply peripheral fatty acid active tissues with 
triglyceride-rich lipoproteins. The VLDL receptor was reported to bind VLDL, IDL, 
and β-VLDL, but not LDL [32, 33].  
VLDLR expression was detected in endothelial cells and smooth muscle cells of 
healthy arteries and veins as well as in plaques and macrophage-derived foam 
cells [34]. Furthermore, the expression of VLDLR (and scavenger receptor) 
mRNA was suggested to be strongly induced in atherosclerotic lesions. As well 
as LRP1, the VLDLR was supposed to play a role in formation of macrophage- 
and smooth muscle cell-derived foam cells [35]. In particular, it was reported to 
contribute to foam cell formation by β-VLDL uptake leading to an accumulation 
of cholesterol esters in the respective cells [36]. In contrast to the LDLR, the 
VLDLR is not downregulated by sterols. Beyond its role in lipoprotein metabo-
lism and atherosclerosis, the VLDLR has been proposed to function in cardiac 
fatty acid metabolism, neuronal migration, insulin resistance, and obesity [37]. 
 
1.3.3 LDL receptor-related protein 1 (LRP1) 
LRP1 has a relative molecule mass of 600kDa and has been detected in liver, 
lung, brain, hepatocytes, fibroblasts, neurons, macrophages, and smooth mus-
cle cells [38]. It recognizes at least 40 different ligands. Several ApoE-
containing lipoproteins (chylomicrons, VLDL-remnants, β-VLDL) are among 
them. Furthermore, it was reported to bind cytoplasmic adaptor proteins and to 
interact with other transmembrane receptors suggesting a role in signalling [22]. 
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In addition, its deletion was shown to be lethal in mice. This finding indicates an 
important role in development [39]. Beyond its presumptive function as remnant 
receptor, LRP1 performs other atherosclerosis-relevant tasks. It regulates vas-
cular smooth muscle cell growth and migration by controlling PDGF signalling. 
Thus, LRP1 contributes significantly to the protection of the vasculature [40-43]. 
In macrophages, LRP1 was reported to mediate the uptake of chylomicron 
remnants [44]. Furthermore, the higher intracellular lipid deposition in vascular 
smooth muscle cells (VSMC) from atherosclerotic plaques was attributed to in-
creased LRP1 expression levels. Thus, LRP1-mediated LDL uptake was con-
sidered to contribute to lipid accumulation in the arterial wall [45]. Notably, LRP1 
expression itself was reported to be elevated by exposure to high LDL concen-
trations and accumulation of cholesterol esters in SMC [46]. 
 
1.3.4 LDL receptor-related protein 2 (LRP2) 
LRP2 (also termed megalin or gp330) is a large (600kDa) endocytic receptor 
expressed in epithelial cells, especially on their apical surface. Amongst others, 
it has been detected in kidney, lung and gallbladder. In the kidney, it is believed 
to execute a relevant function: facilitating the recapture of filtered molecules in 
the proximal tubules. Beyond internalization, LRP2 has been suggested to act 
in signal transduction pathways and to play a role in the central nervous system 
as well as in neurodegenerative diseases. ApoB and apoE also belong to the 
numerous known ligands of LRP2. Furthermore, it has been reported to inter-
nalize apoAI and apoAII. Thus, a contribution to the regulation of HDL metabo-
lism is conceivable [47, 48]. In a complex with its partner cubilin, megalin was 
shown to internalize LDL [49] and HDL [50]. All these findings indicate a role in 
lipoprotein metabolism.  
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1.4 Carbamylation of LDL 
 
Besides common risk factors, chronic kidney disease (CKD) has been recog-
nised as severe preconditioning background for the development of atheroscle-
rosis and, as a consequence, cardiovascular disease. Patients with end-stage 
renal disease frequently die from cardiovascular complications. Carbamylated 
LDL has been suggested to link CKD to uremia-induced atherosclerosis. Fur-
thermore, modified lipoproteins are counted among the uremia-related risk fac-
tors like hyperhomocysteinemia, increased oxidative stress, endothelial injury 
and dysfunction, and chronic microinflammation [51-58]. 
In addition to carbamylated LDL (cLDL), the following chemical modifications of 
LDL have been reported: oxidized LDL (oxLDL) [59], acetylated LDL, ethylated 
LDL, methylated LDL [60], and glycated LDL [61]. They are commoly accepted 
to cause endothelial cell injury, thereby favouring atherosclerotic processes [62]. 
Moreover, they elevate the expression of adhesion molecules for monocyte 
binding [63] and increase macrophage scavenger receptor expression [64]. As 
a result, the proliferation of VSMC is stimulated, which is also mediated by ox-
LDL directly [65]. Recently, they were shown to lower the activity and expres-
sion of lysosomal acid lipase in EC and SMC [66].  
 
                    Fig. 10: Reaction scheme of LDL carbamylation, modified from [58]. 
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Fig. 10 shows the formation of cLDL. Urea spontaneously dissociates to ammo-
nia and cyanate. Isocyanic acid reacts irreversibly with the N-terminal amino 
groups of LDL forming epsilon-amino-carbamyl-lysines. These modifications 
can accumulate during a lipoprotein’s lifespan [67]. This nonenzymatic reaction 
is proportional to the urea concentration in the blood plasma. Thus, uremic pa-
tients show a significantly elevated level of cLDL. Cyanate is also obtained by 
myeloperoxidase-catalyzed oxidation of thiocyanate, whose levels are elevated 
in smokers [68].  
The clearance of mildly carbamylated LDL is decreased because of reduced 
LDL receptor binding. However, there is no binding to scavenger receptors yet. 
Hence, it remains longer in the bloodstream. With increasing carbamylation, the 
affinity to scavenger receptors rises and binding to the LDL receptor is reduced 
to a minimum [69-71]. In vitro studies revealed that carbamylated LDL causes 
injury and dysfunction of EC [72]. Furthermore, it is believed to induce endothe-
lial cell death by mediation of cell proliferation via the mitogen-activated protein 
kinase (MAPK) pathway [73]. Recent studies suggest an involvement of endo-
nuclease G in cLDL-induced cell death [74]. cLDL exposure to EC in vitro was 
also shown to induce ICAM-1 and VCAM-1 expression leading to monocyte ad-
hesion [75]. In addition, cLDL affects smooth muscle cells by inducing monocyte 
adhesion (ICAM-1, VCAM-1 expression) and mediating proliferation [76, 77].  
Increasing carbamylation lowers the affinity to the LDL-R, but increases binding 
to scavenger receptors [78]. These scavenger receptors are supposed to act 
pro-atherogenic. They bind several modified and native lipoproteins and partial-
ly promote inflammation, cell adhesion, oxidative stress and foam cell formation. 
cLDL is mainly scavenged by lectin-like oxidized LDL receptor 1 (LOX-1) and 
partially by CD36, SREC-1, and SR-A1. It was postulated to cause in vitro up-
regulation of LOX-1. However, the translocation of cLDL into the vascular wall is 
not mediated by LOX-1. Nevertheless, the LOX-1 upregulation was thought to 
contribute importantly to the cytotoxicity of cLDL to EC [79-83]. Scavenger re-
ceptor classes and their structures are illustrated in figure 11.  
 - 16 - 
 
 
             Fig. 11: Structures and classes of scavenger receptors [82]. 
 
 
 
1.5 The impact of estrogen 
It is commonly accepted that premenopausal women have a lower risk for de-
veloping cardiovascular disease than men of the same age group. This sex-
related difference is mainly attributed to estrogen [84-86]. 17β-estradiol (E2, 
structure see figure 12) has been reported to fulfil several protective functions 
(see figure 13). 
 
 
              Fig. 12: The structure of the steroid hormone 17β-estradiol (E2) [87]. 
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Fig. 13: Protective functions mediated by estrogen [88]. 
 
Vascular reactivity is influenced directly by targeting endothelial cells. Further-
more, estrogen
 
modulates vascular tone by affecting the extracellular matrix and 
vascular smooth muscle cells. It impacts serum lipid concentrations, fibrinolysis, 
and coagulation. In addition, it causes vasodilation by increasing the release of 
vasodilatory substances (NO, prostacyclin) and decreasing vasoconstrictor lev-
els (endothelin, angiotensin II) [89-91]. Moreover, it performs anti-oxidative ac-
tions [92]. A role in remodelling of the actin cytoskeleton and endothelial cell 
migration has also been revealed [93]. Recently, an estrogen-mediated reduc-
tion of cholesterol ester accumulation in human monocyte-derived macrophag-
es has been demonstrated [94]. Sex differences in vascular contraction have 
been suggested to be directly related to the effects of estrogen on vasculature 
[95]. However, the application of hormone replacement therapy remains contro-
versial as there are non-beneficial effects observed as well [96]. 
The effects of estrogen are regulated by genomic and non-genomic pathways 
(see fig.14). The genomic effects require transcriptional processes, whereas the 
non-genomic are so-called “rapid responses”. Three receptors are known: two 
ligand-activated transcription factors ERα and ERβ (estrogen receptor α and β) 
that belong to the nuclear hormone receptor superfamily and a G-protein cou-
pled estrogen receptor (GPER or GPR30) [97]. ERα and ERβ were reported to 
act in EC and SMC [90], GPER was detected in the vasculature as well. GPER 
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is known to bind estrogen with high affinity and has been proposed to mediate 
some of the non-genomic effects [98]. It was recently described to relax coro-
nary artery smooth muscle cells after activation by estrogen. Thus, it mediates 
estrogen signalling in coronary arteries leading to relaxation independent from 
endothelium and NO [99]. Simultaneously, another group studied the effects of 
estrogen on SMC and found that contraction was mediated by mineralocorticoid 
receptor, ERα and GPER [100]. A crucial role in regulating the atheroprotective 
action of estrogen in LDLR-deficient mice was assigned to the endothelial ERα 
by Billon-Galés et. al. [101].  However, Villablanca and co-workers assessed 
ERα as not essential for estrogen-mediated atheroprotection [102].  
The stimulatory action of estrogen on LDL-R expression was first described in 
1980 [103]. In the meantime, this effect has been investigated more closely. It 
has been suggested that a specific interaction between ERα and transcription 
factor Sp1 (specifity protein 1, transcription factor bound to the LDL-R promoter) 
leads to transcriptional activation of LDL-R by estrogen. Furthermore, an inter-
action of SREBP-1 with the ERα-Sp1 complex could be responsible for a trans-
activation of LDL-R [104]. Interestingly, the basal transcription of the LDL-R re-
quires protein kinase C (PKC) activity, whereas the estrogen-stimulated way 
was found to depend on tyrosine kinase (TK) activity [105].  
VLDL-R mRNA expression in the rabbit heart was reported to be strongly in-
creased by estrogen [106]. Furthermore, LRP1 levels in the mouse brain were 
elevated by estradiol replacement [107] indicating that other LDL-R gene family 
members are influenced by estrogen as well.  
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Fig. 14: Model of genomic and non-genomic estrogen actions on EC and SMC [89]. Inter-
rupted arrows mean inhibition.  
Genomic: estrogen is bound to endothelial cytosolic/nuclear ER leading to MAPK activation fol-
lowed by an increase of gene transcription and elevated eNOS production. Non-genomic: es-
trogen binds to endothelial surface membrane ER resulting in raised Ca2+ release from the en-
doplasmic reticulum and stimulation of the MAPK/Akt pathway leading to eNOS activation.  
NO diffuses into VSMC, where it increases cGMP (cyclic guanosine monophosphate). This 
leads to VSMC relaxation due to decreased intracellular Ca2+ concentration. Estrogen also in-
creases endothelial prostacyclin (PGI2) release leading to cAMP (cyclic adenosine monophos-
phate) elevation in VSMC and thus relaxation. Further consequences of estrogen action are 
inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) production (resulting in 
blockage of NO inactivation and peroxynitrite formation) and endothelium-derived hyperpolari-
zation factor (EDHF)-mediated VSMC relaxation due to hyperpolarization (K+ channels).  
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1.6 Shear stress and endothelial function 
 
The predominant development of atherosclerotic lesions in regions with altered 
blood flow has already been observed in 1969 [108]. Today, it is well-known 
that lesions preferentially occur at bifurcations, bends, and branches of the arte-
rial tree. This is based on the exposure of these sites to lower or disturbed 
blood flow resulting in low or oscillatory shear stress on the vessel wall. In con-
trast, regions subjected to high shear stress resulting from unidirectional flow 
are protected from atherosclerotic lesion development and inflammation [109]. 
Shear stress is defined as “the force per unit area created when a tangential 
force of blood flow acts on the endothelium” [110]. It can be expressed as 
 
																									 = 4μ/	
 
 
 
in units of dynes/cm² [111]. The mechanical forces acting on the endothelium 
are converted by mechanotransduction to intracellular biochemical signals (see 
figure 15). These signals subsequently influence gene expression. Cells are 
currently estimated to sense shear stress via ion channels, calveolae, G-protein 
coupled receptors, tyrosin-kinase receptors, cell-adhesion molecules, gly-
cocalyx, and primary cilia [112].  
µ… viscosity 
Q… flow rate 
r… vessel radius 
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       Fig. 15: Ways of shear stress mechanotransduction and involved signalling  
       pathways [112]. 
 
Besides alterations in gene expression, the exposition of endothelial cells to 
shear stress causes changes in cell morphology. The cells align in flow direction 
(see fig. 16). This alignment has recently been suggested to be promoted by c-
Jun N-terminal kinase 2 (JNK2) [113].  
 
Fig. 16: Endothelial cells change morphology when subjected to shear stress [110]. 
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Laminar shear stress is considered to influence gene expression in an athero-
protective way (see fig. 17). As summarized by Shi Pan [110], it inhibits tumor 
necrosis factor alpha (TNFα) -mediated inflammatory events and stimulates 
eNOS-mediated NO production and prostacyclin (PGI2) secretion. Elevated NO 
levels result, among others, in decreased monocyte attraction/adhesion and 
suppression of VSMC proliferation. Furthermore, laminar shear stress activates 
antioxidative enzymes. Their action is of great relevance since ROS augment 
monocyte adhesion, SMC proliferation, and lipid oxidation [114]. In contrast, low 
shear stress supports monocyte binding and transmigration. In addition, it 
stimulates the production of ROS and SMC growth factors (PDGF, endothelin 
(ET-1)) [110]. The opposite actions of high and low shear stress are also illus-
trated in figures 18 and 19.  
Shear stress was reported to elevate the expression of the LDL-R leading to an 
increase of LDL clearance [115]. In particular, the integrin-mediated activation 
of SREBP-1 by shear stress was suggested to cause LDL-R upregulation [116]. 
To date, nothing is known about a possible influence on other LDL-R gene fami-
ly members. Coculture-experiments indicate a mutual affection of smooth mus-
cle cells and shear stress-exposed endothelial cells [117]. As a rather exact re-
construction of the natural conditions, this finding is of great importance.  
 
Fig. 17: The atheroprotective actions of high laminar shear stress [110]. 
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Fig. 18: This table (took from [118]) summarizes the effects  
of shear stress on the vasculature. 
 
 
Fig. 19: Comparison of the consequences of high and low shear stress for the endotheli-
um and smooth muscle cells [119]. A) High shear stress causes endothelial cells to release 
factors that counteract leukocyte migration, coagulation and VSMC proliferation. B) In contrast, 
low shear stress leads to a release of factors that favour the exact opposite. (tPA… tissue 
plasminogen activator, TGF-β… transforming growth factor beta, Ang II… angiotensin II) 
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Following up on research findings gained in previous diploma theses [122, 133], 
this thesis aims to investigate processes emerging by the influence of estrogen 
on the LDL-R gene family in HCAEC under high and low shear stress as well as 
static culture conditions and in HCASMC under static conditions. An essential 
part of the work was performed in the laboratory of Dr. Gürkan Sengölge (Medi-
cal University of Vienna, Department of Internal Medicine III).  
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2. Methods 
 
2.1 Preparation and modification of lipoproteins 
 
2.1.1 Preparation of lipoproteins (according to Goldstein et. al. [120]) 
Lipoproteins were separated and isolated by sequential density gradient ultra-
centrifugation with potassium bromide. Therefore, human plasma was mixed 
with a calculated amount of KBr and put in a quick seal tube. The tube was 
heat-sealed and centrifuged over night at 14°C as d escribed in [120]. The 
amount of KBr was calculated using this formula: 
	 = 	
 × 2 − 1
1 − 0,312	 × 2
 
 
 
 
 
 
  
 
  
At first, VLDL had to be removed. The EDTA-plasma (density of 1.006) was 
therefore adjusted to a density of 1.019 using a calculated amount of solid KBr. 
If necessary, fulfilling of the quick seal tube (37mL, Beckman) was done with 
KBr/EDTA buffer (density of 1,019). The tube was heat-sealed and centrifuged 
at 50K for 20h using a 50.2 Ti rotor from Beckman. Figure 20 visualizes the 
fractions formed during centrifugation.  
m(KBr)…. mass of KBr in g 
V(plasma)… volume of plasma in mL 
D2… designated density 
D1… current density 
density of HDL: 1.063 – 1.210 g/mL 
density of LDL: 1.019 – 1.063 g/mL 
density of VLDL: 1.006 – 1.019 g/mL 
 - 26 - 
 
After aspirating the VLDL fraction collected on the top of the tube, the bottom 
fraction was adjusted to a density of 1.063 and subsequently centrifuged at 60K 
at 14°C for 24h using an 80 Ti rotor from Beckman. 
The top fraction containing LDL was aspirated using a syringe and immediately 
desalted (PD-10 desalting column, GE healthcare). The column had previously 
been equilibrated with LDL buffer (150mM NaCl, 0,24mM EDTA, pH 7.4). At last, 
HDL was separated at a density of 1.210 for 36h at 55K and 14°C and desalted 
in the same way. 
After this, the concentrations of LDL and HDL were determined spectro-
photometrically using the Modified Lowry Protein Assay Kit (Thermo Scientific, 
Pierce Protein Research Products) according to manufacturer’s instructions. 
Standard solutions with defined concentrations of BSA (0, 10, 20, 40 and 80 
mg) were used to generate a calibration line.  
 
 
 
 
  
Fig. 20: Tubes with separated lipoprotein fractions after centrifugation. 
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2.1.2 Detection of modification 
Carbamylated LDL was obtained from Prof. Bernhard Gmeiner (Institute of 
Medical Chemistry, Vienna). LDL was carbamylated by using potassium cya-
nate (KOCN).  
The chemical modification should be visualized by a relative electrophoretic 
mobility assay. For this purpose, lipoprotein samples were diluted in 50mM Tris-
HCl (pH 7.4), mixed with sample buffer and loaded onto a polyacrylamide gel. 
Subsequently, the gel was run at 150-180V for 1-2h (depending on experiment). 
Electrophoresis was performed using 4% native gels (composition of gel and 
materials see below) and SDS-containing gels (6% or gradient 4.5-18%). The 
composition of the SDS-containing gels and buffers is described in chapter 
“2.4.2 Western-blotting”. Additionally, the lipoproteins were analysed on a 1.5% 
agarose gel. 
Sample buffer (native) Running buffer (native) pH 8.4 
2.5 mL 125mM Tris/HCl pH 8.4 
2mL Glycerine 
1mg Bromophenol blue 
ddH2O added to 10Ml 
3.0g Tris 
14.4g Glycine 
fill up to 1L with ddH2O 
 
Reagent stacking gel 4% separation gel 4% 
ddH2O [mL] 1.55 3.10 
0,5M Tris pH 6.8 [mL] 0.625 - 
1,5M Tris pH 8.8 [mL] - 1.25 
PAA (30%) [mL] 
(29.2% Acrylamide, 
0.8% Methylenbisacrylamide) 
0.325 0.650 
APS (10%) [µL] 12.5 25 
TEMED [µL] 5 5 
The gel was dyed in Coomassie Brilliant Blue (10% Acetic acid, 25% Isopropa-
nol, 0.862g Coomassie Blue R250, and 1950 mL ddH2O) for 1h on a shaker. 
Subsequently, it was destained in Destain Solution (30% Methanol, 10% Acetic 
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acid). For preservation, the gel was put on filter paper and dried at 70°C for 2h 
in a vacuum gel dryer.  
 
2.2 Cell culture techniques 
 
2.2.1 Materials, media and standard operations 
 Name manufacturer 
cell lines   
 Human coronary artery endothelial cells 
(HCAEC) 
PromoCell 
 Human coronary artery smooth muscle 
cells (HCASMC) 
PromoCell 
media   
 Endothelial Cell Growth Medium MV PromoCell 
 Smooth Muscle Cell Growth Medium 2 PromoCell 
 Endothelial Medium without L-Glutamine 
(“serum-free medium” , SFM) 
PAA 
buffers   
 Trypsin-EDTA 1x PAA 
 Dulbecco’s Phosphate-Buffered Saline 1x 
(“PBS”), Gibco 
Invitrogen 
materials   
 Sterile cell culture flasks with filtered caps 
(25cm²)  
BD Falcon 
 Sterile cell culture flasks with filtered caps 
(75cm²) 
Nunc 
 Cell scraper BD Falcon 
 Centrifuge and test tubes 15mL, sterile BD Falcon 
 Disposable plastic pipettes (1/5/25mL) BD Falcon 
 FiberCell Endothelial Cartridges (PS+, 
C2025) 
FiberCell Systems 
 Microprocessor-controlled pump FiberCell Systems 
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HCAEC and HCASMC were stored in liquid nitrogen. After rapid thawing in a 
water bath (37°C), they were washed in PBS and cent rifuged carefully at 
800rpm for 4min without brake (Hettich Rotana RTC). The cells were re-
suspended in pre-warmed (37°C) growth medium (Endot helial Cell Growth Me-
dium MV for HCAEC and Smooth Muscle Cell Growth Medium 2 for HCASMC) 
and transferred into a cell culture flask followed by incubation at 37°C with 
5%CO2 and 95% relative humidity. Cell population was routinely controlled un-
der the microscope. 
For cell splitting, the medium was aspirated using a Pasteur pipette. The cells 
were subsequently washed with PBS followed by treatment with Trypsin-EDTA 
(up to 1min in incubator). When all cells were detached (control under micro-
scope), the cells were suspended in fresh growth medium and distributed to 
several culture flasks. 
 
2.2.2 Experiments under static flow conditions 
These experiments were performed with both HCAEC and HCASMC. The ex-
periments under static conditions were carried out in cell culture flasks. Cells 
were grown in growth medium until confluent, then they received serum-free 
medium. 24 hours later, this medium was replaced by serum-free medium with 
experiment-specific additions (50nM E2, 25µg/mL nLDL or cLDL, 20µg/mL HDL) 
followed by incubation for 18 hours.  
Then, the cells were harvested. Therefore, the medium was discarded and the 
cells were washed with PBS followed by scratching with a cell scraper. The ob-
tained suspension of cells in PBS was collected in a 15mL tube and kept on ice 
till centrifugation at 1200 rpm for 5min, 4°C (Hett ich centrifuge, 46 RSC). The 
supernatant was discarded, except the last 0,5mL, in which the cell pellet was 
re-suspended and transferred into a 1,5mL Eppendorf tube. After centrifugation 
at 13000rpm for 2min (Eppendorf 5415D), the whole supernatant was aspirated 
and the pellet was frozen at -80°C. 
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2.2.3 Cartridges: cells under shear stress 
Shear stress experiments were only performed with HCAEC. In a living organ-
ism, endothelial cells are always exposed to hemodynamic shear stress. There-
fore, growing endothelial cells under static culture conditions is not a satisfying 
model for studying the gene expression behaviour of these cells. FiberCell car-
tridges allow more authentic culture conditions. 
A bundle of hollow fibers (small, cylindrical filters with an internal diameter of 
700µm) is surrounded by an extracapillary space. However, the inside of the 
fibers and the extracapillary space can be filled separately. The inside of the fi-
bers is filled by liquid entering through the end ports (A and D), the extracapil-
lary space by the side ports (B and C, see figure 22). The exchange between 
these two spaces is limited by the filter’s pore size of 0.1µm. After seeding en-
dothelial cells onto the inside of the fiber wall (see figure 21), medium is 
pumped through the fibers at a controllable flow rate to generate shear stress. 
One endothelial cartridge contains 20 fibers, which result in a total lumen sur-
face area of 70cm². The FiberCell cartridges would also allow a co-culture (e.g. 
with smooth muscle cells) by growing the other cells in the extracapillary space 
[121]. 
First, the cartridge had to be activated. Therefore, the capillary space was 
flushed with 70% ethanol by using syringes which were attached to the ports. 
After that, the cartridge was rinsed with sterile water. Then, the inner membrane 
surface was coated with fibronectin (1 hour at 37°C ). After coating, the protein 
solution was rinsed out with medium. Preculture was done overnight.  
Freshly harvested cells were brought into the cartridge and incubated without 
flow. Every 30 minutes, the cartridge was rotated about 90° for 2h. After cell at-
tachment and perfusion, the cartridges were connected to a pump. The cells 
were now exposed to shear stress for 10 days (low shear stress: 2.5 dynes/cm², 
high shear stress: 25 dynes/cm²). From day 9 to 10, the experiment-specific ad-
ditions (50nM estrogen, 25µg/mL nLDL or cLDL) were added. Cells were har-
vested by flushing the cartridge with Trypsin-EDTA. The whole procedure of 
working with the cartridge is also described in [122]. 
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Fig. 21: Cell layer (blue) in a hollow fiber [121]. 
 
 
 
 
     Fig. 22: FiberCell Endothelial Cartridge [121]. 
 
  
2.3 Gene expression analysis by RT-PCR 
 
2.3.1 Theoretical background 
The polymerase chain reaction was developed in the 1980ies in the group of 
Kary B. Mullis [123, 124]. This method facilitates rapid amplification of a desired 
DNA fragment and allows qualitative analysis of the DNA template (whether it 
contains a certain sequence). A conventional PCR master mix is at least com-
posed of 
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• a DNA template 
• two oligonucleotides, called “primers”, who flank the DNA se-
quence to be amplified 
• a heat-stable polymerase 
• reaction buffer containing appropriate concentrations of Mg+ ions 
and the four nucleotide triphosphates [125]. 
 
The reaction itself is controlled by subjecting the reaction mix to a defined tem-
perature/time programme (“temperature cycling”). At first, high temperature is 
applied to separate the DNA strands. However, primer annealing and elonga-
tion of the new strands occur at lower temperatures (see thermal profile). 
 
A major disadvantage of the classic PCR is the necessity of a post-PCR analy-
sis (e.g. by electrophoresis). That is why Higuchi et. al. [126] intended to solve 
this problem by showing that the increase of the PCR product can be monitored 
during the amplification process by adding an intercalating dye. The today 
commonly used real-time PCR is based on this observation. However, adding 
intercalating dyes is just one method to monitor product increase in real-time. In 
our experiment, Taqman probes were used. The foundation for this method was 
laid by Holland et. al. in 1991, when they postulated that the 5’ → 3’ exonucle-
ase activity of Thermus aquaticus DNA polymerase could be used to detect 
specific PCR products [127]. In 1995, this finding was picked up by Livak et. al. 
who concentrated on the design of specific oligonucleotide probes for detection 
of PCR products [128]. They placed a reporter dye at the 5’ end of a specific 
oligonucleotide probe and a quencher dye at 3’. When the fluorescent reporter 
dye at 5’ gets excited by irradiation, the fluorescent emission will be quenched if 
the 3’ quencher dye is close enough (fluorescence resonance energy transfer). 
However, when the probe is cleaved by the Taq polymerase’s nucleolytic activi-
ty during strand extension, the dyes move away from each other and there is no 
quenching. Thus, fluorescence increases and can be measured (see also 
scheme in figure 23 and figure 24).  
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Fig. 23: The “5’ nuclease assay” from Livak 
in 1995 [128]. 
Fig. 24: The principle of the “modern Taq-
man” [129]. 
 
 
After completion of the PCR process, the CT (cycle threshold) values are dis-
played. “Cycle threshold” means the number of the cycles required to reach a 
certain threshold (see figure 25). How many cycles a sample needs depends on 
the initial amount of DNA. Thus, CT values can be compared for quantification. 
However, it has to be considered that the DNA concentration in the particular 
samples is usually not equal. To make them comparable, one can normalize to 
an internal reference gene (in our case the housekeeping gene β-actin). Hence, 
the gene expression ratio of our gene of interest is determined relative to the 
reference gene. Unlike the reference gene whose expression should stay con-
stant, the gene of interest is expected to be possibly affected by the conditions 
studied [125]. The evaluation method of choice for such an experiment is the 2-
∆∆CT method. Its derivation was comprehensibly described by Livak and 
Schmittgen in 2001 [130].  
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           Fig. 25: PCR response curve, took from [125]. 
 
 
 
2.3.2 Reverse transcription 
Since the expression of a gene has to be studied, not gDNA but cDNA (synthe-
sized from RNA) is required for PCR. For this procedure, the FastLane Cell 
cDNA Kit (Qiagen) was utilized. The cell pellets were thawed and mixed with 
1mL of Buffer FCP. After incubation at room temperature for 5-10 min, the 
“FastLane lysates” were ready to use for reverse transcription. 
According to the protocol, the genomic DNA elimination reaction was set up as 
follows: 
gDNA Wipeout Buffer 7x 4µL 
FastLane lysate 20µL 
RNAse-free water 4µL 
Total volume 28µL 
 
This mixture had to be incubated at 42°C for 5 min (Eppendorf Thermomixer) 
and subsequently stored on ice. 
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The mixture for the reverse transcription reaction was composed as follows: 
 
Quantiscript RT Buffer 5x 8µL 
RT Primer Mix 2µL 
FastLane lysate (Template RNA) 28µL 
Quantiscript Reverse Transcriptase 2µL 
Total volume 40µL 
 
Incubation was done at 42°C for 30min followed by h eating at 95°C for 3 min 
(enzyme inactivation). 
 
2.3.3 PCR procedure 
 
name of material manufacturer  
TaqMan Fast Universal PCR Master Mix (2X), No 
AmpErase UNG 
Applied Biosystems 
TaqMan Pre-Developed Assay Reagents 
Human ACTB 20x (probe dye: FAM-MGB) 
Applied Biosystems 
TaqMan Gene Expression Products  
“Assays-on-Demand” (probe dye: FAM) 
Hs01045922_m1 (human VLDL-R 20x) 
Hs01092523_m1 (human LDL-R 20x) 
Hs01059338_g1 (human LRP 20x) 
Hs00189742_m1 (human LRP2 20x) 
Applied Biosystems 
7500 Fast Real Time PCR System (Thermocycler) Applied Biosystems 
7500 Fast System SDS Software Applied Biosystems 
MicroAmp Fast Optical 96-well plates 0,1mL Applied Biosystems 
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PCR mix composition:  
cDNA 1 µL 
Nuclease-free water 3,5 µL 
Primer 20x (ACTB or receptor) 0,5 µL 
TaqMan Master Mix 2x 5µL 
Total volume 10µL 
 
Negative controls were always included. Nuclease-free water was used instead 
of cDNA. 
Thermal profile:    
Step Temperature [°C] Duration [sec] Repetition 
Initial denaturation 95 20  1 
Denaturation 95 3  40 
Annealing/Elongation 60 30  40 
 
2.3.4 Statistical analysis 
PCR data were analysed using the 2-∆∆CT method (derivation see [130]). For sta-
tistical analysis, at least 5 individual results were required. The end-results are 
expressed as the averages of these individual results +/- SEM (standard error 
of the mean). A two-tailed Student T-test was utilized to determine the statistical 
significance of the data. A p-value < 0.05 was considered as significant, p < 
0.01 as highly significant.  
 
2.4 Protein expression analysis 
 
2.4.1 Protein extraction and quantification 
The cell pellets (obtained from three 75cm² flasks) were mixed with 100µL of 
buffer B (200mM Tris maleate pH 6.5, 2mM CaCl2, 1.4% Triton X-100). Before 
addition, the buffer had been completed with “complete EDTA-free” Protein In-
hibitor Cocktail Tablets (Roche, 1 tablet per 50mL buffer solution). After keeping 
the mixture on ice for 10 min, it was centrifuged at 90000 rpm (Beckman Ultra-
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centrifuge, TLA 100 rotor) and 4°C for 40min. The s upernatants were taken off 
and the pellets were discarded.  
The Quick Start Bradford 1x Dye Reagent (BIORAD) was used for protein quan-
tification. 1mL reagent mixed with 5µL of BSA (2mg/mL, BIORAD) served as 
standard. 1µL of sample protein solutions was added to 1mL reagent for protein 
analysis. The OD was determined with the spectrophotometer at 595nm. The 
following formula was utilized for calculation of protein concentration: 
μ !"	"
#	 !"	"
	× 	
#	$
μ%$
	= $	&'!&. μ	$		μ% 
 
2.4.2 Western blotting 
Western blotting is a method for protein detection first described by the group of 
George R. Stark and co-workers in Stanford in 1979 [131]. The principle has 
remained the same: proteins are separated by SDS-PAGE and subsequently 
transferred to a membrane, where they are detected using specific antibodies. 
 
Name of required material: Source: 
Mini Trans-Blot Electrophoretic Transfer Cell BIO-RAD 
Mini-PROTEAN 3 electrophoresis chamber BIO-RAD 
PowerPac power supply BIO-RAD 
Filter papers  Whatman 
Nitrocellulose membrane Hybond C-Extra Amersham 
Precision Plus Protein Unstained Standard BIO-RAD 
Anti- LDL receptor (from mouse) diluted 1:500 General Hospital 
Anti-LRP2 (polyclonal, from mouse) diluted 1:1000 abcam 
Anti-LDL receptor (from rabbit) diluted 1:500 self-made 
Anti-rabbit HRP-conjugated, diluted 1:50000 Sigma 
Anti-mouse HRP-conjugated, diluted 1:20000 Jackson 
Super Signal West Pico Chemiluminescent Substrate  Thermo Scientific 
CL-XPosure Films 5x7 inches Thermo Scientific 
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Sample Buffer (2x) Sample Buffer reducing (2x) Running Buffer (1x) 
31.2% Glycerine 
6% SDS  
20mM Tris-HCl pH7.5  
Bromophenol-blue  
ddH2O to 20mL 
31.2% Glycerine 
6% SDS  
20mM Tris-HCl pH7.5  
25mM Dithiothreitol (DTT) 
Bromophenol-blue  
ddH2O to 20mL 
 
25mM Tris-HCl  
192mM Glycine 
1% SDS 
1x Transfer buffer Ponceau S solution 10x TBS 
25mM Tris-HCl 
192mM Glycine 
0.2% Ponceau S 
3% Trichloracetic acid 
1.37 M NaCl 
0.027 M KCl 
0.25 M Tris-HCl pH 7.4 
 
Blocking solution TBS-T  
5% non-fat dry milk  
in 1x TBS-T 
1x TBS with  
0.1% Tween 20 
 
 
SDS-PAA gel 
reagents: 
stacking 
gel  4% 
separation 
gel 6% 
separation gel 
10% 
ddH2O [mL] 1.525 2.625 2.025 
0,5M Tris pH 6.8 [mL] 0.625 - - 
1,5M Tris pH 8.8 [mL] - 1.25 1.25 
PAA (30%) [mL] 
(29.2% Acrylamide, 
0.8% Methylenbisacrylamide) 
0.325 1 1.65 
SDS (10%) [µL] 25 50 50 
APS (10%) [µL] 12.5 25 25 
TEMED [µL] 5 5 5 
 
An appropriate amount of protein from each cell extract was mixed 1:1 with 
loading buffer (in case of reduced samples: denaturation for 3min at 95°C) and 
loaded on the 1mm polyacrylamide gel (composition see table). The gel was run 
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at 150V for approximately one hour (until the blue dye reached the bottom). Af-
ter that, a “sandwich” out of sponges, filter papers, membrane and gel was as-
sembled. Blotting to the nitrocellulose membrane was carried out for 1h at 100V 
and 130mA. The blotting unit was kept in an ice box.  
To check transfer efficiency, the membrane was shortly stained in Ponceau S 
solution and destained in ddH2O. Subsequently, it was blocked in TBS-T/milk 
solution for 1h on a shaker. Then, the primary antibody was diluted appropriate-
ly in blocking solution and put on the membrane over night at 4°C with gentle 
agitation. After that, the membrane was washed three times in TBS-T for 10min 
followed by incubation with the secondary antibody (1-2h at room temperature). 
Finally, the membrane was washed again (3x10min) in TBS-T and treated with 
the detection reagents (Super Signal West Pico Chemiluminescent Substrate, 
Thermo Scientific).  
The chemiluminescence reaction is illustrated in figure 26. HRP catalyses the 
reaction of Luminol to its light-emitting oxidized form. The two components of 
the detection kit were mixed 1:1 and put on the membrane for 2-3min. Then, the 
membrane was transferred into a film cassette together with a CL-Xposure film 
(Thermo Scientific). Exposure was done for at least 30min followed by devel-
opment. 
 
Fig. 26: The principle of the chemiluminescence reaction. Luminol oxidation is catalysed by 
HRP leading to light emission [132]. 
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2.5 Cytotoxicity and apoptose assay 
 
To determine whether our applied concentrations of lipoproteins and estrogen 
exert toxic effects on the cells, a cytotoxicity assay was performed. Therefore, 
HCAEC were cultured in 96-well plates and incubated with lipoproteins and es-
trogen in different combinations (25µg/mL nLDL or cLDL, 20µg/mL HDL, 50nM 
E2) in serum-free medium. Furthermore, growth medium and serum-free medi-
um without additions were used as controls. The tests were carried out as quad-
ruplicates (n=4). Cytotoxicity was determined by measurement of spontaneous 
lactat dehydrogenase (LDH) in medium and total LDH release after cell lysis. 
Calculated was the percentage of spontaneous LDH release in medium in com-
parison to total LDH release in lysed cells. LDH release was detected using the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega) according to the 
manufacturer’s recommendations. Absorbance was measured at the Victor³V 
microplate reader (Perkin-Elmer).  
 
The apoptose assay required the same experimental setup as the cytotoxicity 
assay (HCAEC cultured in a 96-well plate, estrogen and lipoproteins as addi-
tions). Then, the plate was utilized to perform the Apo-ONE Homogenous 
Caspase -3/7 Assay (Promega) according to the manufacturer’s instructions. 
This assay facilitates the detection of apoptosis by measurement of caspase 
activity. Fluorescence is caused by enzymatic cleavage of the substrate and is 
therefore proportional to caspase activity. Fluorescence emission was meas-
ured at the Victor³V microplate reader (Perkin-Elmer).  
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3. Results 
 
 
3.1 Analysis of lipoprotein modification 
The lipoproteins used for cell culture experiments were analysed on poly-
acrylamide gels to visualize their difference/modification. Figure 27 shows a na-
tive PAA gel with native and carbamylated LDL samples. A difference in elec-
trophoretic mobility is recognizable.  
 
 
Fig. 27: Native LDL and carbamylated LDL run 
for 2h at 150V on a 4% native PAA gel. 
 
 
In addition to electrophoretic mobility, lipoproteins should be separated accord-
ing to their size. Therefore, further studies were performed on SDS-PAA gels 
(non-reducing and reducing conditions). Figure 28 visualizes various lipopro-
teins run on a gradient gel and compares non-reduced versus reduced condi-
tion. 
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Fig. 28: Native and modified LDLs on a gradient  
PAA gel (4.5-18%), run for 2h at 180V. 
1… 15µg nLDL 
2… 15µg cLDL 
 
3… 15µg nLDL (reduced) 
4… 15µg cLDL (reduced) 
 
 
In figure 29, the same samples were analysed on a 6% SDS-PAA gel. As al-
ready observable in figure 28, the individual modifications lead to a distinct be-
haviour. Interestingly, the reduction of the lipoproteins results in stronger for-
mation of multiple bands.  
 
Fig. 29: Native and modified LDLs on  
a 6% PAA gel, run for ~1h at 180V. 
1… 10µg nLDL 
2… 10µg cLDL 
3… 10µg nLDL (reduced) 
4… 10µg cLDL (reduced) 
 
 
Finally, figure 30 visualizes the clear difference in REM of native and car-
bamylated LDL on an agarose gel. Furthermore, the increasing degree of modi-
fication by treatment with higher concentrated KOCN is evident.  
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Fig. 30: Native and carbamylated LDL run on a 1.5% agarose gel. The LDL treated with a 
higher concentration of KOCN showed an increased change in relative electrophoretic mobility.  
 
 
3.2 Regulation of the LDL-R gene expression 
 
 
Fig. 31: LDL-R expression in EC with estrogen. All values are expressed as average +/- 
SEM and are relative to the condition HSS nLDL, which was set to 1. The p-values are calculat-
ed between HSS nLDL and the respective condition.  
Abbreviations: HSS… high shear stress, LSS… low shear stress, stat… static culture 
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Figure 31 illustrates LDL-R gene expression in HCAEC under estrogen influ-
ence. Shear stress alterations and LDL carbamylation affected LDL-R expres-
sion profoundly. To determine the effect of estrogen, these results were com-
pared with gene expression findings from studies without estrogen (see fig. 31). 
The results for HSS nLDL/cLDL and LSS nLDL/cLDL were generated in a for-
mer study [133].   
 
 
 
Fig. 32: All studies on LDL-R gene expression in endothelial cells without or with estro-
gen. A part of the test results without estrogen (HSS nLDL/cLDL, LSS nLDL/cLDL) were gener-
ated in former studies [133]. All values are expressed relative to HSS nLDL without E2, which 
was set to 1. The p-values were calculated between the conditions without and with estrogen 
and should indicate the significance of estrogen influence.  
Abbreviations: HSS… high shear stress, LSS… low shear stress, st… static culture conditions, 
nLDL… native LDL, cLDL… carbamylated LDL, E… 17β-estradiol (E2) 
 
Figure 32 provides an overview of all studied parameters. Strikingly, a tremen-
dous difference between HSS, LSS and static culture conditions was observed. 
Certainly, the static culture is far away from the physiological conditions of cor-
onary artery endothelial cells. However, the deterioration from HSS to LSS con-
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stitutes an interesting finding. Carbamylation decreased LDL-R expression. Es-
trogen tended to have a positive effect, except for the condition HSS with cLDL.  
Figure 33 illustrates LDL-R expression in HCASMC. cLDL lead to a significant 
reduction. Furthermore, estrogen decreased receptor expression in absence of 
lipoproteins and in presence of nLDL. However, it increased LDL-R expression 
in presence of cLDL. 
 
Fig. 33: Studies of LDL-R gene expression in coronary artery smooth muscle cells. All values 
are depicted relative to the control (SFM… serum-free medium), which was set to 1. The p-
values express the significance of estrogen action. 
 
3.3 Regulation of the VLDL-R gene expression 
Figure 34 illustrates a strong reduction of VLDL-R expression by low shear 
stress in EC. In contrast, LDL carbamylation had no effect. The impact of estro-
gen is demonstrated in figures 35a and 35b. Estrogen treatment elevated 
VLDL-R gene expression under static conditions independently from lipoprotein 
type (see figure 35b). In contrast, estrogen seems to exert a negative effect on 
VLDL-R expression under shear stress conditions (see figure 35a). However, 
more data for shear stress without estrogen conditions are required for a statis-
tical confirmation of these results.  
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Fig. 34: Gene expression of the VLDL-R in endothelial cells under different culture condi-
tions (all with E2). All results are expressed relative to HSS nLDL, which was set to 1. The p-
values indicate the significance of the comparison between the reference (HSS nLDL) and the 
particular condition.  
 
 
Fig. 35a: Summary of all studies performed on the VLDL-R gene expression in HCAEC. 
All results are expressed relative to HSS nLDL without estrogen. A part of the results without 
estrogen (HSS nLDL/cLDL, LSS nLDL/cLDL) were generated in former studies [133]. Only 
one data set was available for these conditions. Therefore, a solid statistical analysis could 
not be performed. The other results were generated in this study, at least five data sets were 
available. The mean values were compared to the single results.  
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Fig. 36: VLDL-R gene expression in SMC. All results are expressed relative to the serum-free 
medium control, which was set to 1. The p-values were calculated between a condition without 
estrogen and the respective condition with estrogen.  
 
 
 
Fig. 35b: The influence of estrogen and carbamylation on VLDL-R expression in EC un-
der static culture conditions. The condition stat nLDL was used as reference, p-values refer 
to the influence of estrogen. 
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In smooth muscle cells (see figure 36), VLDL-R expression was raised by lipo-
proteins. Especially carbamylated LDL lead to a massive increase. Estrogen 
caused an elevation in absence of lipoproteins. However, when combined with 
lipoproteins, the expression was diminished compared to the control.  
 
3.4 Regulation of the LRP1 gene expression 
 
 
Fig. 37: The influence of carbamylation and shear stress on LRP1 expression in EC with 
estrogen. The condition HSS nLDL was set to 1. p-values express the significance of change in 
reference to HSS nLDL.  
 
Carbamylated LDL nearly abolished LRP1 expression in EC subjected to shear 
stress (see figure 37). A decline of shear stress caused a reduction of gene ex-
pression as well. Under static conditions, estrogen elevated LRP1 expression in 
presence of carbamylated LDL (see figure 38b). In contrast, there was no signif-
icant difference when combined with native LDL. Figure 38a provides an over-
view over all studies of LRP1 expression in HCAEC. Estrogen may influence 
LRP1 expression in different ways depending on culture conditions.  
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Fig. 38a: Summary of all studies performed on LRP1 gene expression in HCAEC. All 
results are expressed relative to HSS nLDL without estrogen. A part of the results without 
estrogen (HSS nLDL/cLDL, LSS nLDL/cLDL) were generated in former studies [133]. Only one 
data set was available for these conditions. Therefore, a solid statistical analysis could not be 
performed. The other results were generated in this study, at least five data sets were available. 
The mean values were compared to the single results. 
 
 
Fig. 38b: The influence of estrogen and carbamylation on LRP1 expression in EC under 
static culture conditions. P-values indicate the significance of estrogen’s influence, stat nLDL 
serves as reference.  
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Figure 39 illustrates LRP1 expression levels in SMC. Native LDL decreased 
LRP1 expression. Furthermore, the combination of estrogen and lipoproteins 
(nLDL as well as cLDL) caused a strong reduction. 
 
 
Fig. 39: LRP1 expression in SMC. The serum-free medium control serves as reference for all 
values. The significance of estrogen’s effect is indicated by the p-value.  
 
 
3.5 LRP2 expression 
LRP2 gene expression was also investigated by RT-qPCR. It was neither de-
tected in endothelial cells nor in smooth muscle cells (data not shown).  
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3.6 Protein detection  
 
HCAEC lysates from static culture experiments were analysed by Western blot-
ting to confirm the gene expression results on protein level. Consistent with the 
gene expression results, LRP2 was not detected in endothelial cells by West-
ern-blot (data not shown). The LDL-R gene expression under static culture con-
ditions was found to be highly reduced compared to shear stress experiments. 
Thus, the LDL-R was not detectable because of insufficient protein amounts 
(data not shown).  
 
 
3.7 Cytotoxicity and apoptose assay 
 
The cytotoxicity assay was performed to assure that the experimental additions 
do not act cytotoxic. It revealed that none of the studied additions executes a 
particular cytotoxic effect on HCAEC in the applied concentration. As illustrated 
in figure 40, the effects of the additions range in the same order of magnitude 
as the growth medium and the serum-free medium do. 
Moreover, the additions were investigated with regard to a possible apoptose-
causing potential. The results of the apopotose assay are shown in figure 41. 
None of the studied conditions leads to a noticeable increase in caspase activity.  
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Fig. 40: Cytotoxicity assay. The results are expressed as averages +/- SEM.  
 
 
 
 
Fig. 41: Apoptose assay. The results are expressed as averages +/- SEM.  
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4. Discussion 
 
The aim of the project was to discover how modified lipoproteins, estrogen and 
altered shear stress influence the gene expression of certain receptors in the 
cells of the coronary artery wall. Therefore, HCAEC were cultivated under static 
and dynamic (high/low shear stress) conditions and HCASMC were grown in 
static culture. In these experiments, native and carbamylated lipoproteins were 
used. Their modification was successfully visualized by electrophoresis. Cyto-
toxicity and apoptose assays showed that the experimental additions (17-β es-
tradiol, native LDL, carbamylated LDL, HDL) did not function particularly toxic 
on endothelial cells in comparison to addition-free cell culture media.  
cDNA was obtained from HCAEC (shear stress and static conditions) and 
HCASMC (static conditions) and used for expression analyses by real-time 
quantitative PCR. Gene expression levels of the LDL-R, VLDL-R, LRP1 and 
LRP2 (which are members of the LDL-R gene family) were investigated.  
The LDL-R occurred in both cell types and was affected by all studied parame-
ters. First, its expression in endothelial cells in static culture was dramatically 
reduced compared to more physiological conditions (shear stress). Thus, static 
culture is very far from the physiological situation of EC and therefore limited in 
informative value. Nevertheless, the LDL-R was downregulated with decreasing 
shear stress level (see fig.31 and fig. 32). This finding is consistent with previ-
ous knowledge [115, 116], as shear stress has been reported to cause an 
SREBP-1-mediated increase in LDL-R expression. However, these investiga-
tors applied shear stress for up to 24 or 48 hours. Our study investigates the 
effect of chronic shear stress (10 days). Furthermore, the results of our study 
also strengthen the hypothesis that high shear stress acts atheroprotective (in-
creased LDL clearance) and low shear stress favours atherogenesis (de-
creased LDL clearance).  
Our findings suggest that carbamylated LDL decreases LDL-R expression. 
Therefore, the carbamylation of LDL should be considered as atherogen since it 
reduces lipoprotein clearance. In contrast, estrogen affected LDL-R expression 
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positively. In combination with HSS and native LDL, the upregulation by estro-
gen was highly significant (see figure 32). This finding is consistent with litera-
ture, as an estrogen-mediated increase of LDL-R expression has already been 
reported in the rat liver and HepG2 cells [103, 104]. However, estrogen reduced 
LDL-R expression dramatically when combined with cLDL. This finding indi-
cates that chronic kidney disease or smoking could have a particularly negative 
effect, more on women than men.  
In HCASMC, LDL-R expression was decreased by cLDL in absence of estrogen. 
Moreover, estrogen reduced LDL-R expression in combination with serum-free 
medium and nLDL, but elevated expression when combined with cLDL (see fig. 
33). Lipid uptake in SMC is an essential step in disease progression. Therefore, 
the observed reduction of LDL-R expression by estrogen has to be considered 
as protective. However, cLDL antagonises this effect. Our suggestion of estro-
gen’s protective effect concerning lipid uptake in SMC is strengthened by Cor-
coran et. al. [94], who reported that estrogen reduced cholesteryl ester accumu-
lation in human monocyte-derived macrophages.  
The VLDL-R expression in estrogen-treated HCAEC was strongly affected by 
shear stress (see figure 34). However, LDL carbamylation had no effect. This is 
not astonishing as LDL is not recognized by the VLDL-R [32, 33]. The obvious 
effect of shear stress alteration on VLDL-R expression could possibly be medi-
ated by the same mechanism as in the LDL-R. A regulation by SREBP-1 would 
be imaginable, as the VLDL-R gene contains two SRE-1-like sequences [33]. 
Estrogen had previously been reported to increase VLDL-R mRNA in rabbit 
heart [106]. Consistent with this finding, it elevated VLDL-R levels in EC in our 
experiment (static culture, see figure 35b). However, our studies provide a clue 
that estrogen could also exert an opposite influence on VLDL-R expression un-
der shear stress conditions. As shown in figure 35a, estrogen radically dimin-
ished VLDL-R expression when subjected to high shear stress and treated with 
native LDL. In consideration of the recent suggestion that the VLDL-R promotes 
leukocyte transmigration and inflammation [134], estrogen’s action is protective. 
However, a repetition of the shear stress experiment without estrogen is indis-
pensable for statistics.  
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VLDL-R gene expression in HCASMC was affected by both lipoproteins and es-
trogen (see figure 36). Estrogen alone caused an increase, whereas the combi-
nation with lipoproteins led to a decrease of receptor expression. This observa-
tion can be explained as a protection mechanism against excess lipoprotein up-
take. Furthermore, Lipoproteins alone strongly raised VLDL-R expression. This 
effect was stronger in cLDL than in nLDL. The VLDL-R was suggested to play a 
role in SMC-derived foam cell formation by contributing to lipoprotein accumula-
tion [35, 36]. An estrogen-mediated decrease of VLDL-R expression can there-
fore be valuated as protective. However, the upregulation by nLDL and cLDL is 
not comprehensible as the VLDL-R is not regulated by LDL. Anyway, this effect 
could promote disease progression and is stronger induced by cLDL than by 
nLDL. 
LRP1 expression in HCAEC is markedly reduced by carbamylation and low 
shear stress (see figure 37 and figure 38a). Since LRP1 fulfils protective tasks 
in the vasculature [40-43], LSS and cLDL act adversely. Under HSS conditions, 
we observed that LRP1 expression was slightly reduced by estrogen when 
combined with nLDL and strongly reduced in combination with cLDL. Again, we 
provide evidence for a particular negative effect of cLDL on women. Admittedly, 
more data are required to confirm these findings statistically. In contrast, estro-
gen increased LRP1 expression significantly when combined with cLDL in static 
culture (see figure 38b). A stimulatory effect of estradiol on LRP1 in the mouse 
brain has been reported in 2007 by Cheng et. al. [107].  
LRP1 is supposed to contribute to lipid accumulation in the artery wall by medi-
ating LDL uptake in smooth muscle cells [45]. In our experiment, estrogen re-
duced LRP1 expression in HCASMC significantly when combined with lipopro-
teins (see figure 39). In consideration of LRP1’s role in SMC-derived foam cell 
formation, estrogen executes a protective function.  
In contrast, LRP2 gene expression was neither found in endothelial cells, nor in 
smooth muscle cells. Furthermore, LRP2 was not detected on protein level. As 
literature provides no evidence of LRP2 expression in HCAEC and HCASMC, 
these results suggest an absence of LRP2 expression in these cells.  
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In conclusion, the results of our experiments provide meaningful clues concern-
ing the role of the studied parameters in atherosclerosis development. Our data 
support the hypotheses of the atheroprotective action mediated by high shear 
stress and the unfavourable effect of low shear stress. In addition, we provide 
evidence for the harmful effect of carbamylated LDL by revealing its influence 
on the regulation of the LDL-R gene family expression. Furthermore, we point 
out several mechanisms of estrogen’s protective action on endothelial cells and 
smooth muscle cells.  
To obtain a sufficient amount of data for performing meaningful statistical anal-
yses, some shear stress experiments without estrogen from a former study 
[133] will have to be repeated. Additionally, it remains open if all gene expres-
sion results can be confirmed on protein level. The static cell culture experiment 
was repeated to obtain more material for finishing LDL-R detection. Further-
more, it is intended to perform Western-blot experiments for detection of VLDL-
R and LRP1 protein expression in HCAEC. The protein analyses are only per-
formed with material from static experiments because the yield of cell material 
in shear stress experiments is extremely low. However, these procedures will 
be the subject of prospective theses.  
The experimental design already aims to simulate the physiological conditions. 
However, it could be improved by establishing a co-culture (EC in hollow fibers 
and SMC in extracapillary space). Furthermore, modified lipoproteins isolated 
from CKD patients could be used for further experiments. These optimizations 
could improve the validity of the experimental data.  
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Abbreviations 
 
ACAT acyl-CoA-cholesterol-acyltransferase 
ACTB beta-actin 
AngII angiotensin 2 
apo apolipoprotein 
BSA bovine serum albumin 
cDNA complementary DNA  
CKD chronic kidney disease 
cLDL carbamylated LDL 
CM chylomicrons 
CSF colony stimulating factor 
CVD cardiovascular disease 
ddH2O double-distilled / deionized water 
E2 17β-estradiol (estrogen) 
EC endothelial cells 
ECM extracellular matrix 
EDHF endothelium-derived hyperpolarizing factor 
EGF epidermal growth factor 
eNOS endothelial nitric oxide synthase 
ER estrogen receptor 
ESRD end-stage renal disease 
ET-1 endothelin 
FH familial hypercholesterolemia 
gDNA genomic DNA  
gLDL glycated LDL 
GPER G-protein coupled estrogen receptor 
HCAEC human coronary artery endothelial cells 
HCASMC human coronary artery smooth muscle cells 
HDL high density lipoprotein 
HMG CoA reductase 3-hydroxy-3-methyl-glutaryl-CoA reductase 
HRP horseradish peroxidase 
HSS high shear stress 
ICAM-1 intercellular adhesion molecule 1 
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IDL intermediate density lipoprotein 
JNK2 c-Jun N-terminal kinase 2 
LCAT lecithin-cholesterol-acyltransferase 
LDL low densitiy lipoprotein 
LDL-R low densitiy lipoprotein receptor 
LOX-1 lectin-like oxidized LDL receptor-1 
LPL lipoprotein lipase 
LRP1 low densitiy lipoprotein receptor-related protein 1 
LRP2 low densitiy lipoprotein receptor-related protein 2 
LSS low shear stress 
MAPK mitogen-activated protein kinase 
MCP-1 macrophage chemoattractant protein 1 
mLDL methylated LDL 
NF-κB nuclear factor kappa B 
nLDL native LDL 
NO nitric oxide 
oxLDL oxidized LDL 
PAA polyacrylamide   
PAGE polyacrylamide gel electrophoresis 
PCR polymerase chain reaction 
PDGF platelet-derived growth factor 
PGI2 prostacyclin 
PKC protein kinase C 
ROS reactive oxygen species 
RT-PCR reverse transcriptase / real-time polymerase chain reaction 
SDS sodium dodecyl sulfate  
SEM standard error of the mean 
SFM serum-free medium 
SMC smooth muscle cells 
Sp1 specifity protein 1 (transcription factor) 
SR scavenger receptor 
SRE sterol regulatory element   
SREBP sterol regulatory element binding protein 
st static 
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TF tissue factor 
TGF-β transforming growth factor beta 
TK tyrosine kinase 
TNFα tumor necrosis factor alpha 
tPA tissue plasminogen activator 
VCAM-1 vascular cell adhesion molecule-1 
VLDL very low density lipoprotein 
VLDL-R very low density lipoprotein receptor 
VSMC vascular smooth muscle cells 
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